Related Experiment Video
Updated: Dec 20, 2025
05:17
Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
Published on: May 14, 2019
9.0K
Cellular microparticles for tumor targeting delivery: from bench to bedside
Zhijie Zhang1, Chen Xiao1, Tuying Yong1
1National Engineering Research Center for Nanomedicine, College of Life Science and Technology, Huazhong University of Science and Technology, 1037 Luoyu Road, Wuhan, 430074, China. zifuli@hust.edu.cn lugan@hust.edu.cn.
Chemical Communications (Cambridge, England)
|June 2, 2020
Summary
Cell-derived microparticles (MPs) show promise as natural drug delivery systems for cancer therapy. Engineered MPs effectively target tumors and have achieved clinical success in lung cancer patients.
Area of Science:
- Biotechnology
- Nanomedicine
- Oncology
Background:
- Cell-derived microparticles (MPs) are emerging as potent natural drug delivery systems for cancer therapy.
- Engineered MPs have demonstrated efficient delivery of antitumor agents in preclinical models.
Purpose of the Study:
- To review microparticle (MP)-mediated tumor targeting delivery.
- To summarize MP impact on tumor progression and metastasis.
- To discuss preparation, labeling, characterization, and cargo encapsulation strategies for MPs.
Main Methods:
- Review of engineered cell-derived MPs for tumor therapy.
- Analysis of MP preparation, labeling, and characterization techniques.
- Evaluation of various cargo encapsulation strategies and their limitations.
Main Results:
- Autologous tumor cell-derived MPs carrying chemotherapeutic drugs are safe and effective in lung cancer patients.
- MPs from various cell types (platelets, endothelial cells, macrophages, dendritic cells) show advantages in tumor targeting.
- Diverse therapeutic agents, including drugs, oncolytic viruses, and nucleic acids, can be delivered via MPs.
Conclusions:
- Microparticle-mediated drug delivery represents a promising biotherapy for malignancies.
- Further research is needed to address challenges and explore opportunities for clinical translation of MP-based therapies.
